...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Clinical trials site
Reply New Message
Back To Forum List View
Clinical trials site
5
chicagoest
Aug 19, 2022 10:51PM

The study was last updated: July 14, 2022.

 

"A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.

Crossref DOI link: https://doi.org/10.1200/JCO.2022.40.16_SUPPL.1023

Published Print: 2022-06-01"

 

"The trial is being expanded to Ph. 2b to accrue an additional 80 TNBC at diagnosis patients. Clinical trial information: NCT03901469"

 

Koo

5 Recommendations
Re: Clinical trials site
3
KOO-KOO2
Aug 20, 2022 07:25AM
Re: Clinical trials site
5
chicagoest
Aug 20, 2022 08:02AM
Re: Clinical trials site
5
KOO-KOO2
Aug 20, 2022 08:34AM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply